Work for Regenxbio Inc.?

Claim Your Profile

Regenxbio Inc. Logo Image

Regenxbio Inc.

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2016 Annual Report, Interactive Annual Report and Form 10K

Regenxbio Inc.

Regenxbio Inc. has reached its limit for free report views.

Regenxbio Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

  • Regenxbio Inc.

About Regenxbio Inc.

51-200 Employees
Based in Rockville, Maryland

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.

Ticker:
RGNX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
--None-- (See More --None-- Companies)
Sector:
--None-- (See More --None-- Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol